• Explore /
  • Poster
  • / Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study.

Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study.

Abstract Poster

Authors

null

Jie Jin

Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Jie Jin , Yi Zhang , Qike Zhang , Qingchi Liu , Hu Zhou , Sujun Gao , Wei Wang , Huibing Dang , Yuqing Chen , Jishi Wang , Peng Zhao , Haiping Yang , Liangming Ma , Qingwei Zhao , Shanshan Suo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT04851535

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7062)

DOI

10.1200/JCO.2023.41.16_suppl.7062

Abstract #

7062

Poster Bd #

192

Abstract Disclosures

Similar Posters

First Author: Justin M. Watts

First Author: Gertjan VAN HAL

First Author: Yi Zhang

First Author: Justin M. Watts